Daily Stock List
CorTronix™ Biomedical Advancement Technologies, Inc. (CBAT)
Today we are reporting on CorTronix™ Biomedical Advancement Technologies, Inc. (CBAT), here at the QualityStocks Daily Newsletter.
Based in Doral, Florida, CorTronix™ Biomedical Advancement Technologies, Inc. is a BioMedical Corporation with a core competency in Mobile Cardio Devices. The Company is in the development stages of creating a complete product line, which will consist of multiple innovative mobile devices with the capacity to acquire and process patients' data by way of a consolidated "Single Source" Network.
The Company entered into an acquisition agreement with Cortronix Technologies, Inc. (CorTronix) on August 15, 2012. CorTronix incorporated solely for the purpose of this acquisition and had no operations. The assets of CorTronix are CorLink™ a multi-product advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies.
The Company integrates existing medical procedures with innovative wireless technology through CorTronix™'s proprietary Network (CorLink™). Their intention is creating the next generation Telemetric Medical Devices. CorTronix™ is in the final stages of developing the infrastructure of their Global Health Network. The Company believes this Network will significantly increase the overall ability for Medical Professionals to properly diagnose and analyze Patients data remotely and in real time.
Currently, CorTronix™ is developing software designed to run on different mobile software platforms. These include, but are not limited to the Android™ Operating System. CorTronix™ BioMedical's proprietary software will be able to be used on any existing tablet that a health care provider already may use. Furthermore, the Company will be creating their CorTab™. It will have all necessary technology integrated into a single unit that will be available for sale or lease through CorTronix™ Biomedical Advancement Technologies directly.
The Company's Corlink™ is an advanced telemetric system used to transmit, analyze, report and store all types of physiological studies. Their CorTab™ is a hand held tablet computer powered by Android and equipped with the latest mobile technology. CorTab™ will have custom-built software applications for ECG, Stress Test, as well as Holter analysis. This will enable cardiologists to have the necessary tools for patient diagnosis on the go.
In addition, the Company has their CorTronix™ CorPak™. It will enable physicians to monitor patient's cardiac status from any location through receiving and analyzing data packages every 30 minutes. This device will be small and very portable. Their CorCare™ Home Monitoring System will be a home based system that will monitor most physiological parameters. Moreover, their CorCheck™ Industrial Health Check System can be applied to any industry. Employees will be identified via a fingerprint and facial recognition system, scanned for alcohol levels in the blood, while at the same time acquiring standard ECG.
CorTronix™ Biomedical Advancement Technologies, Inc. (CBAT), closed Thursday's trading session at $0.19, up 18.75%, on 519,905 volume with 55 trades. The average volume for the last 60 days is 24,065 and the stock's 52-week low/high is $0.12/$0.455.
Medical Marijuana, Inc. (MJNA)
PennyStocks24, SmallCapVoice, Penny Stocks VIP, OTCJournal, and OTC Stock Review reported recently on Medical Marijuana, Inc. (MJNA), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Medical Marijuana, Inc.'s mission is to be the premier cannabis and hemp industry innovators. The Company is leveraging their team of professionals to source, evaluate, and purchase value-added companies and products. The Company is the first publicly held enterprise vested in the medical marijuana and industrial hemp markets. Medical Marijuana consists of a diverse portfolio of products, services, technology and businesses solely focusing on the cannabis and hemp industries.
Medical Marijuana provides over 50 proprietary and patented cannabinoid "delivery methods" that are more "socially and medically acceptable" than smoking. Medical Marijuana does not grow, sell or distribute any substances that violate U.S. Law or the controlled substance act. Products range from patented and proprietary based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries.
Their services range from medical clinic management to the capitalization and development of existing industry business and product leaders. Their services include development of cannabinoid based health and wellness products, and the development of medical grade compounds. Medical Marijuana services include the licensing of their proprietary testing, genetics, labeling, and packaging, tracking, and production and standardization methods for the medicinal herb industry.
Medical Marijuana's PhytoSPHERE Systems and their advanced plant growth technologies save significantly on resources necessary for the production of medical grade cannabis. PhytoSPHERE Systems' provides a medical grade end product, extracts and compounds. PhytoSPHERE Systems also includes pre-and-post production tracking, gemplasm references, packaging, and processing, to ensure consistency and genetic purity. PhytoSPHERE Systems is a pharmaceutical grade vertical Bio-Technology Company specializing in the standardization, production and extraction of medicinal cannabinoids.
Last week, Medical Marijuana informed of recent developments in the research involving Cannabidiol (CBD) and other Phyto-cannabinoids. The Company announced positive developments in recent studies using Cannabidiol (CBD) Compounds. NBC News, ABC News and The Huffington Post reported California Pacific Medical Center's findings that CBD stops metastasis in aggressive cancers.
The following is from a Huffington Post interview with Dr. McAllister and Dr. Desprez:
A pair of scientists at California Pacific Medical Center in San Francisco has found that a compound derived from marijuana could stop metastasis in many kinds of aggressive cancer, potentially altering the fatality of the disease forever.
Pierre Desprez, one of the scientists behind the discovery, said to The Huffington Post. "It took us about 20 years of research to figure this out, but we are very excited. We want to get started with trials as soon as possible."
Dr. Desprez and Dr. McAllister first published a paper about the finding in 2007. Since that time, their team has found that CBD works in the lab and in animals. Dr. McAllister and colleague Pierre Desprez, PhD from California Pacific Medical Center have previously mentioned, "Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy."
Medical Marijuana, Inc. (MJNA), closed Thursday's trading session at $0.1493, up 6.64%, on 2,362,998 volume with 290 trades. The average volume for the last 60 days is 7,019,401 and the stock's 52-week low/high is $0.0242/$0.50.
Promithian Global Ventures, Inc. (PGVI)
PennyStocks24 and OTCMagic reported today on Promithian Global Ventures, Inc. (PGVI), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Promithian Global Ventures, Inc. is a development stage mining company that lists on the OTC Markets. The Company is presently exploring the "Main Zone" silver copper vein on the historic Warburton property in the southern Yukon. The intrusion related quartz-carbonate vein hosts high grades of silver, copper, and lesser amounts of zinc, arsenic and antimony. Promithian is exploring the "Main Zone" to determine the most efficient "Narrow Vein Mining" method that they will use to exploit the vein.
Promithian Global Ventures has their headquarters in Salt Lake City, Utah. The Company formerly went by the name Midex Gold Corp. They changed their name to Promithian Global Ventures, Inc. last month. In May 2013, a Joint Venture Agreement was negotiated between Promithian Mining, Inc. and Promithian Global Ventures.
The Company's other projects include the Deslaurier Coal Deposit. The principles of Promithian, Inc. acquired from the Government of Canada, in 2001, an Exploration License covering approximately 40,000 acres in the Bonnet Plume Basin of the Yukon Territory. Promithian, Inc. is planning an exploration, engineering, and development project that would prove sufficient tonnage and quality of coal for a six million tonne per year mining operation, which would export thermal coal into the Pacific market.
In 2002, Promithian, Inc., the Nacho Nyak Dun Development Corporation, and the Yukon Department of Energy Mines and Resources engaged Hatch Associates Ltd. to conduct a high-level evaluation of Promithian's plan for a mining–steel manufacturing operation in northeastern Yukon. The plan involves developing the Crest Iron Deposit and the Deslaurier Coal Deposit for producing high-pressure natural gas line-pipe as well as other steel products.
Recently, Promithian Global Ventures announced that their intention is to carry out a bulk-sampling program on the "Main Zone" high-grade vein this year. If the tests are successful they will design and build a small scale, low capital cost, high profit, narrow vein underground mine around the "Main Zone" Vein.
Last week, Promithian Global Ventures announced strategic planning for the Company's upcoming Warburton bulk sampling project. The taking of the two to five tonne bulk sample will from the "Main Zone" deposit, based on the geological continuity of the vein. The final objective of the bulk-sampling program is to obtain the quantitative information necessary for the economic evaluation of the "Main Zone" deposit. The objective is to determine whether the "Main Zone" ore is a suitable Direct Shipping Ore (DSO) that will lead to a production decision that leads to profitable mining operations.
Promithian Global Ventures, Inc. (PGVI), closed Thursday's trading session at $0.27, up 9.76%, on 561,148 volume with 138 trades. The average volume for the last 60 days is 18,992 and the stock's 52-week low/high is $0.017/$2.00.
Western Potash Corp. (WPX.TO)
We are highlighting Western Potash Corp. (WPX.TO), here at the QualityStocks Daily Newsletter.
A development stage potash company, Western Potash Corp. is focusing on building Canada's most efficient potash solution mine. The expectation is that commercial production will begin, subject to financing, in 2016. Western Potash lists on the Toronto Stock Exchange; the Company has offices in Vancouver, British Columbia, and in Regina, Saskatchewan.
Potash refers to a group of potassium (K) bearing minerals and chemicals. The dominant potash in the market is the compound potassium chloride or KCl. Fertilizer producers mine the potassium from naturally occurring potash ore deposits. Saskatchewan hosts the world's premier potash basins and hosts 50 percent of the world's reserves.
Western Potash is concentrating on building a solution mine on their
Milestone Property in southern Saskatchewan. In December 2012, along with AMEC of Americas, the Company completed a Feasibility Study (FS) on the project. Western Potash earlier announced the completion of the Environmental Assessment on the Milestone Property.
The Milestone property is approximately 30 km southeast of Regina and 80 km Southeast of Mosaic's Belle Plaine Mining Lease. Western Potash's KLSA 008 Mining Lease includes all Crown land within the 157,500 acres of the Milestone Project Property. The Company acquired 2,550 acres for the building of the plant site.
Earlier this week, Western Potash announced that China BlueChemical Ltd. and Benewood Holdings Corp. Ltd., via a joint venture company, CBC (Canada) Holding Corp. (CBCHC), agreed to make a strategic equity investment of C$ 31,979,022 in Western Potash. This will result in CBCHC holding a 19.9 percent ownership in the Company on a non-diluted basis.
China Blue is a majority owned subsidiary of China National Offshore Oil Corporation (CNOOC). CNOOC is the largest offshore oil and gas producer in China. Benewood is a wholly owned subsidiary of GUOXIN International Investment Corp. Ltd., a financial investment company registered in Hong Kong (Guoxin).
Moreover, Western Potash and CBCHC agreed to an off-take term sheet. CBCHC, or a purchaser designated by them, will enter into an off-take agreement for the purchase of the lesser of 30 percent or one million tonnes of potash each year from Western Potash's Milestone project for a 20-year term. The off-take agreement will automatically extend for five-year periods unless either party elects not to extend.
Western Potash Corp. (WPX.TO), closed Thursday's trading session at $0.55, up 1.85%, on 202,362 volume. The stock's 52-week low/high is $0.40/$1.23.
El Nino Ventures, Inc. (ELN.V)
Today we are highlighting El Nino Ventures, Inc. (ELN.V), here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, El Nino Ventures, Inc. is a global exploration enterprise. The Company focuses on exploring for zinc, silver, copper, gold, lead in New Brunswick, Canada, and copper in the Democratic Republic of Congo (DRC). El Nino Ventures' shares also trade on the OTC Markets' OTCQX International (ELNOF). The Company is based in Vancouver, British Columbia.
Currently, in New Brunswick, El Nino Ventures is working with Votorantim, the second largest mining company in Brazil. In Canada Votorantim operates by way of their subsidiary Votorantim Metals Canada (VMC).
In New Brunswick, El Nino Ventures has their Murray Brook Project. This project has premier infrastructure; it is the fifth largest massive sulfide deposit in the Bathurst Mining Camp. VMC can earn up to a 50 percent interest in the Murray Brook Project through funding $2,250,000 of exploration expenditures over a 3-year period. El Nino Ventures is participating by paying 50 percent of VMC's exploration costs. VMC and El Nino have a second option to acquire a further 20 percent by incurring an additional $2.25 million in exploration costs.
El Nino Ventures also has their Bathurst Zinc Project in New Brunswick, as well as the Kasala Copper Project located in the Central African Copper Belt.
Yesterday, El Nino Ventures announced the results of an NI 43-101 Preliminary Economic Assessment (PEA) for the Murray Brook polymetallic massive sulfide deposit. The results of the PEA demonstrate the potential technical and economic viability of establishing a new mine and mill complex on the Murray Brook property. The projected cash flows indicate an after-tax NPV at a 5 percent discount rate of $96.4 million. The projected cash flows additionally indicate an Internal Rate of Return (IRR) of 11.4 percent and a payback period of 5.4 years.
The PEA assumes the commencement of the open pit mining operations at an average annual process plant production rate of 2,000,000 tonnes per annum over a mine life of approximately 9.5 years. The mining operation is envisioned as a conventional open pit. The mined material will undergo processing at a new 6,000 tonnes per day flotation plant located on the Project site. The three concentrates to be produced are copper-silver; lead-silver; and zinc-silver.
El Nino Ventures, Inc. (ELN.V), closed Thursday's trading session at $0.035, even for the day, on 46,666 volume. The stock's 52-week low/high is $0.02/$0.14.
Ocean Power Technologies, Inc. (OPTT)
SmarTrend Newsletters, National Inflation Association, and FeedBlitz reported earlier on Ocean Power Technologies, Inc. (OPTT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Ocean Power Technologies, Inc. is developing and working to commercialize proprietary systems that generate electricity through harnessing the renewable energy of ocean waves. Listed on the Nasdaq Global Market, the Company's PowerBuoy systems utilize proprietary technologies to convert the mechanical energy created by the rising and falling of ocean waves into electricity. Since fiscal 2002, the U.S. Navy and other government agencies have accounted for a major portion of Ocean Power's revenues. Ocean Power Technologies has their corporate headquarters in Pennington, New Jersey.
Currently, the Company offers and continues to develop two PowerBuoy product lines. These consist of their utility PowerBuoy system and their autonomous PowerBuoy system. They additionally offer operations and maintenance services for their PowerBuoy systems. On top of this, the Company markets their undersea substation pod product and undersea power connection infrastructure services to other companies in the marine energy sector.
The PowerBuoy is an offshore wave energy converter. The majority of it is submerged below the water's surface. Inside, a piston-like structure moves as the PowerBuoy bobs with the rise and fall of the waves. This movement drives a generator, producing electricity. The electricity is sent to shore via an underwater cable.
An Ocean Power Technologies "wave power plant" will consist of an assortment of identical PowerBuoys electrically connected to provide the preferred power capacity. The Company's "smart" PowerBuoy uses computer-based, proprietary technologies. Technological innovations include patented electronics systems for control and wave power conversion, patented wave power conversion and transfer systems, distinctive generating systems that function effectively at low and variable speeds, and a modular construction process.
Ocean Power Technologies is focusing on marketing their PowerBuoy technology to grid-connected utility markets featuring the Mark 3 PowerBuoy, and the autonomous market requiring lower levels of continuous power for deep-ocean applications (this includes maritime security and homeland defense, offshore oil and gas operations, aquaculture and oceanographic data sampling).
Additionally, the Company is focusing on marketing their PowerBuoy technology to infrastructure products and services. Ocean Power Technologies has many years of experience in marine energy ocean operations, cable installations, grid interconnection and permitting and site development. Their Undersea Substation Pod product is available for sale to all companies in the marine energy sector.
Ocean Power Technologies, Inc. (OPTT), closed Thursday's trading session at $1.5345, down 2.94%, on 22,424 volume with 34 trades. The average volume for the last 60 days is 43,505 and the stock's 52-week low/high is $1.45/$3.97.
El Capitan Precious Metals, Inc. (ECPN)
Today we are reporting on El Capitan Precious Metals, Inc. (ECPN), here at the QualityStocks Daily Newsletter.
El Capitan Precious Metals, Inc. is an exploration stage company principally engaged in the exploration of precious metals and other minerals. The Company primarily holds interest in the El Capitan gold-silver property located near Capitan, New Mexico. El Capitan Precious Metals' shares trade on the OTC Bulletin Board. The Company has their headquarters in Scottsdale, Arizona.
El Capitan Precious Metals' primary asset is their wholly owned subsidiary El Capitan, Ltd., an Arizona corporation. This subsidiary holds the 100 percent equity interest in the aforementioned El Capitan property. The El Capitan deposit has been known as a potential iron ore resource for a number of decades. The U.S. Bureau of Mines drilled approximately 140 shallow holes through the outcropping, shallow-dipping magnetite skarn deposit in 1944 and 1948.
The El Capitan property consists of 354 Bureau of Land Management (BLM) lode claims and four patented claims. The claim block is in Lincoln County, New Mexico and occupies approximately 3,000 acres in townships T 7 S, T 8 S, and range R 14 E. A number of recovery methods have been utilized in extracting ore from the El Capitan property. These methods include the alkali fusion method, silver lead collection, as well as carbon pre-roast with silver-lead recovery.
At the end of February 2013, El Capitan Precious Metals announced that they obtained results from a well-respected metallurgical lab that used pre-treatment of the ore and the industry accepted method of cyanide vat leaching. The resulting assays, obtained under "Chain of Custody" procedures, demonstrated substantial values of gold along with lesser amounts of other precious metals.
The Company, to increase the value of their mining property, added this method of precious metal recovery process to the silver-lead recovery process (the Sundancer Method) currently being used. To maximize the recovery of all precious metals, El Capitan is working with the metallurgical lab to develop further an encompassing recovery process that will include cyanidation recovery and the silver-lead process.
El Capitan Precious Metals, Inc. (ECPN), closed Thursday's trading session at $0.1672, down 1.07%, on 50,457 volume with 20 trades. The average volume for the last 60 days is 228,311 and the stock's 52-week low/high is $0.131/$0.52.
Validian Corp. (VLDI)
MicrocapVoice, BreakthroughStocksTeam, OTC Advisors, FeedBlitz, ShamrockStocks, and Stock Guru reported previously on Validian Corp. (VLDI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Validian Corp. provides software products for public and private enterprises. The Company is a leader in developing and marketing solutions to protect against the threats of today's digital world. Their corporate mission is to deliver inventive, information protection solutions, which help government agencies, enterprises and individuals reduce the impact of theft, disclosure, non-compliance or malicious tampering with their digital assets. Validian has their headquarters in Ottawa, Ontario.
The Company is the first-to-market with the next generation of cyber security technology for the management and protection of digital information, data and assets. Their technology provides secure access, transfer and storage of digital information on wired, wireless and mobile networks over the Internet. Validian technology enables the next generation of secure Cloud Computing, Cloud Storage, Distributed Computing and Web Application, and WebPortal Access and Usage for desktop and laptop computers, servers, tablets, as well as SmartPhones.
Validian provides solutions that can undergo customization to the client's business process. This is to ensure end-to-end authenticity, integrity and custody of high value digital assets. The Company's solutions include Validian Protect, MediaProtect, and MedicalProtect.
Recently, Validian announced that the Company is scheduled to present at the National Investment Banking Association (NIBA) Conference June 17-19, 2013, at the Marriott Hotel near Wall Street in downtown Manhattan. Validian President and Chief Executive Officer, Mr. Bruce Benn, will present to investors; he will be available for one-on-one meetings throughout the conference. NIBA is the national trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers.
Today, Validian announced an agreement with NYC Radio, LLC. The agreement is for an extensive seven-month radio campaign commencing June 8, 2013. Validian will be presented through the course of the campaign on a Corporate Profile Minute heard on the popular Larry Kudlow radio program on WABC 770am in New York, New York.
Validian Corp. (VLDI), closed Thursday's trading session at $0.06, up 36.36%, on 2,499,875 volume with 79 trades. The average volume for the last 60 days is 403,947 and the stock's 52-week low/high is $0.004/$0.0487.
Yappn Corp. (YPPN)
Today we are reporting on Yappn Corp. (YPPN), here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, Yappn Corp. operates as an online social community. The Company's intention is to operate the social media Website at yappn.com. This site hosts multi-language conversations based on different topics, including interests, brands, and activities in an environment that incentivizes user engagement via rewards and other gamification features. Founded in 2010, The Company previously went by the name Plesk Corp. They changed their corporate name to Yappn Corp. this past March. Yappn has their headquarters in New York City.
Yappn is powered by Ortsbo's translation technology (www.ortsbo.com). Yappn translates all of their topics and discussions in real-time with a button click. Yappn also offers a set of very robust communication tools; users can create opportunities to meet, chat, engage, and consume content in their own virtual location creating worldwide social engagement for private events and closed networks. People can do this individually, in groups and by topic. In addition, users can also connect to leading social networks and engage friends and followers on Facebook, Yahoo!, Twitter and more.
Yappn will be available on all major devices through mobile, portable, and desktop online access. The community of discussion pages and boards cover any user-generated topic in a host of languages. Yappn is for individuals, professional bloggers, corporate/commercial enterprises, non-profits and non-governmental organizations (NGOs).
Furthermore, Yappn is a launch pad for strong commercial opportunities. The Company's boards can be used to promote corporate eCommerce programs.
In May, Yappn announced that their development platform, Yappn, will incorporate Intertainment Media, Inc.'s FanTalk technology creating the Yappn Global Feed platform. The FanTalk technology enables major social media to co-exist in one location in up to 70 languages. The Yappn Global Feed will provide Yappn users with a "rolling ticker tape" of the latest social media activity about specific Yappn topic based discussion boards.
This week, Yappn announced that their development platform, Yappn (www.yappn.com) is now ready to present its online corporate presence. It is set to launch fully this summer. The new website allows users to get a further "sneak peek" into the upcoming open beta release of Yappn.
Yappn Corp. (YPPN), closed Thursday's trading session at $0.95, up 33.80%, on 527,300 volume with 277 trades. The average volume for the last 60 days is 11,770 and the stock's 52-week low/high is $0.0073/$1.00.
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.079, up 4.91%, on 250,301 volume with 87 trades. The stock’s average daily volume over the past 60 days is 535,819, and its 52-week low/high is $0.06/$0.28.
Cardium Therapeutics, Inc. held its Annual Meeting of Stockholders earlier today, where stockholders considered and approved the re-election of the Company's Class I Directors (including Edward W. Gabrielson, M.D. and Lon E. Otremba, each to serve for a three-year term), the compensation paid to the Company's named executive officers, the establishment of a three-year advisory say on pay frequency, the sale of certain Series A preferred stock, and ratification of the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2013. The proposals considered were described in detail in the Company's definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on April 29, 2013.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting Proposals
Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0385, up 1.32%, on 422,512 volume with 36 trades. The stock’s average daily volume over the past 60 days is 2,011,971, and its 52-week low/high is $0.0275/$0.155.
Advaxis Inc. announced today that its Board of Directors has decided to no longer seek stockholder approval to amend the 2011 Omnibus Incentive Plan and will withdraw this proposal from the agenda for its Annual Meeting scheduled for the 14th of June. Chairman and CEO of ADXS, Thomas A. Moore, remarked on how this move to drop proposal 4, that wouldve increased the number of shares by 75M (on a pre-reverse stock split basis), being pulled helps everyone focus on proposals 2 and 3 relating to Advaxis’ certificate of incorporation.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time
Advaxis Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal
Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
DoMark Internatioxnal, Inc. (DOMK)
The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.109, up 0.93%, on 279,522 volume with 64 trades. The stock’s average daily volume over the past 60 days is 369,177, and its 52-week low/high is $0.0322/$2.00.
DoMark International, Inc. was pleased to announce today that their continued conquest of the Apple and Samsung smartphone accessory space continues with the engagement of one of the leading luxury product designers in the world to develop a new range of high end products specifically for the Apple iPad accessory market. This new collection range will complement DoMarks revolutionary light weight infrared and solar panel charger case with built in lithium batteries designed for the everyday Apple iPhone and iPad user and the company's IRiPad luxury charger platform will be going toe to toe with brands like Burberry and Tiffany & Co.
DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.
Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.
Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.
The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer
DoMark International, Inc. Blog
DoMark International, Inc. News:
DoMark International Inc. Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market
DoMark International Inc. Develops New Product for $2.3 Billion iPad Accessories Market
DoMark International Inc. Positions Itself for Substantial Growth
GNCC Capital, Inc. (GNCP)
The QualityStocks Daily Newsletter would like to spotlight GNCC Capital, Inc. (GNCP). Today, GNCC Capital, Inc. closed trading at $0.01, off by 9.09%, on 997,350 volume with 27 trades. The stock’s average daily volume over the past 60 days is 527,637, and its 52-week low/high is $0.0048/$0.09.
GNCC Capital, Inc. expounded further today on their recent announcement (May 20) regarding acquisition of the "White Hills" Gold Exploration Properties, confirming that the company has met a number of the Conditions Precedent required to complete the deal. It is expected that the Company will close this acquisition on June 17, adding a nice chunk to their acreage footprint with this low cost of production. advanced exploration stage property consisting of several lode and placer claims on some 1.68k acres in Arizona.
GNCC Capital, Inc. (GNCP) is a gold and silver exploration company with six different projects, all of which were carefully selected due to their outstanding characteristics. The company’s geologists will supervise an extensive exploration program for these projects to prove up reserves through geological surveys and a substantial number of carefully planned drilling programs.
The company’s initial exploration properties, located in Arizona, consist of Esther Basin, Burnt Well, Clara Gold, Kit Carson, Silverfields, and Potts Mountain. GNCC Capital plans to create significant value for its initial properties portfolio through continued exploration and joint ventures, as well as through acquiring additional gold and silver exploration assets.
GNCC Capital currently holds circa 80% of its assets in gold exploration properties. The strong rise in gold prices over recent years make this company attractive to investors seeking to benefit from the increasing value of precious metals. Backed by a world-class management team with decades of experience in the financial and mining sectors, GNCC Capital is well positioned to capitalize on the upward trend.
The company’s focus is creating value for its shareholders, employees, and business and social partners through responsible and safe exploration, mining, and marketing. While gold exploration is the company’s main focus, GNCC Capital will take advantage of value-creating opportunities in other minerals where it can leverage existing assets, skills, and experience. Disclaimer
GNCC Capital, Inc. Company Blog
GNCC Capital, Inc. News:
GNCC Capital, Inc. Nears Completion of the Acquisition of the White Hills Gold Properties
GNCC Capital, Inc. Reaches Agreement to Acquire White Hills Gold Properties
GNCC Capital, Inc. Secures Additional Funding Commitment
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.171, on 29,500 volume with 5 trades. The stock’s average daily volume over the past 60 days is 48,901, and its 52-week low/high is $0.041/$0.98.
Rafarma Pharmaceuticals, Inc. announced today that production of the antibiotic Ceftriaxone has begun at their state of the art facilities, coinciding nicely with the deal struck between ZAO "SIA International" and OAO "A5 Pharmacy Ltd." (Russian national retail chain), consisting of long-term distribution contracts that give RAFA an overnight national presence in the Russian Federation's booming retail pharmaceutical market. This is a huge deal and the Ceftriaxone, which is used to treat inflammatory infections of the organs of the abdominal cavity, including peritonitis, as well as, inflammatory diseases of the gastrointestinal and bile-excreting tracts, is in high demand.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals, Inc. Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
Rafarma Pharmaceuticals, Inc. Announces Engagement of QualityStocks Investor Relations Services
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Advaxis today reports that its board of directors has determined that after discussions with shareholders and other interested parties, it will no longer seek shareholder approval to amend the company’s 2011 Omnibus Incentive Plan and will withdraw this proposal from the agenda for its Annual Meeting scheduled for June 14, 2013.
Advaxis’ original proposal was that stockholders approve an amendment to the 2011 Omnibus Incentive Plan to increase the number of shares authorized for issuance under the plan by 155 million shares (on a pre-reverse stock split basis), and then later revised this number to 75 million shares (on a pre-reverse stock split basis). This proposal was included as Proposal No. 4 in Advaxis’ definitive proxy statement.
The company believes that the proposals relating to its certificate of incorporation (Proposal No. 2, the Reverse Stock Split Amendment, and Proposal No. 3, the Authorized Share Decrease Amendment) are more likely to be achieved if Proposal No. 4 is removed from the agenda for its upcoming Annual Meeting.
“We believe that management and stockholders’ interests need to be well aligned,” Thomas A. Moore, chairman and CEO of Advaxis, stated in the press release. “We are dropping this proposal so there can be no question about this. We continue to believe that the proxy statement, as supplemented and further amended, is in the best interest of all our stockholders and ask for their support. The board of directors and management of the company strongly urge stockholders to vote in favor of proposals 2 and 3 relating to Advaxis’ certificate of incorporation. Doing so will position Advaxis to raise sufficient capital to execute its business plans.”
Advaxis Tuesday said it has revised Proposal No. 3 to now decrease the proposed total number of authorized shares of common stock post-reverse stock split to 25 million shares (the earlier proxy supplementproposed a total number of 50 million shares of common stock post-reverse stock split).
The company said it believes that shareholder approval of the proposals relating to its certificate of incorporation (Proposal No. 2, the Reverse Stock Split Amendment, and Proposal No. 3, the Authorized Share Decrease Amendment) is more likely to be achieved if the company decreases the total number of authorized shares of common stock on a post-reverse stock split.
“We have revised Proposal 3 in consideration of feedback received from our stockholders. Votes previously cast ‘in favor’ do not need to be re-voted. Votes previously cast ‘against’ can be reversed,” Thomas A. Moore, chairman and CEO of Advaxis, stated in Tuesday’s press release. “The board of directors and management of the company strongly urge stockholders to vote in favor of this revised proposal. Doing so will position the company to raise sufficient capital to execute its business plans.”
The Annual Meeting of Stockholders of Advaxis will be held June 14, 2013, at 10 a.m., Eastern Daylight Time, at the Princeton Marriott, 100 College Road East, Princeton, New Jersey 08540.
For more information visit www.advaxis.com
DoMark International, an investment management company focused on patented and patent pending mass market consumer products for Apple (AAPL) and Samsung Smartphone devices, has retained the services of a leading luxury product designerfor the development of a new range of products for the Apple iPad accessories market.
The new collection will complement DoMark’s current light-weight infrared and solar panel charger case, which features built-in lithium batteries that are specifically designed for the Apple iPhone and iPad, and will utilize patented infrared and solar technologies. To company will target a demographic of the high-end market, competing with brands such as Tiffany & Co. (TIF), Louis Vuitton (LVMHF) and Burberry (BURBY).
“Apple iPad users come in all shapes and sizes and appreciate great design regardless of price points,” DoMark president and CEO, Andy Ritchie, stated in the press release. “We want to ensure we have a product to suit every customer’s diversity.”
DoMark’s objective is to gain a foothold in all levels of the $2.3 billion iPad accessories market by delivering high-quality products for all categories of iPad users.
For more information visit www.domarkintl.com
GNCC Capital primarily is a gold exploration company with a secondary focus on silver exploration; initial exploration properties are located in Arizona. The company today issued an update on its pending acquisition of the White Hills Gold Properties, noting that it has met a number of conditions necessary to complete the transaction. GNCC anticipates closing the acquisition June 17, 2013.
The White Hillsgold exploration property comprises a number of lode and placer claims on 1,680 acres in Arizona, meeting the company’s requirements for potential low cost extraction.
The property will provide GNCC with “a significantly larger base of exciting and potential low cost production gold mining assets” while transitioning the company into a joint-venture, revenue producing arena.
GNCC’s strategy is to generate revenue streams from joint-venture agreements and to allocate the proceeds to the acceleration of exploration for other gold properties in its portfolio, thereby leading to additional joint-venture agreements and cash flow.
In addition to the White Hills properties, GNCC is also focusing on two of its existing gold exploration properties, “Clara” and “Burnt Well,”both of which are in line with management’s immediate and stated objectives of “low cost, extremely viable gold mining properties.”
For more information visit www.gncc-capital.com
Rafarma Pharmaceuticals, a Russia-based manufacturing facility that produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today said it has commenced production of the antibiotic Ceftriaxone.
Ceftriaxone is for the treatment of inflammatory infections of the organs of the abdominal cavity, such as peritonitis, as well as inflammatory diseases of the gastrointestinal and bile-excreting tracts.
Rafarma points to 2011 official statistics that estimate the Ceftriaxone market in Russia at more than USD$51 million each year. As a participant in the Russian Federal Program for “Domestic-Produced Vital Drugs,” Rafarma said it plans to take as much as 50 percent of the Russian market for Ceftriaxone.
Rafarmaalso said it stands to benefit from a recent long-term distribution agreement between ZAO “SIA International” and the Russian national retail chain OAO “A5 Pharmacy Ltd.,” which provides Rafarma with a national presence in the Russian Federation retail pharmaceutical market.
“The agreements with these drug store chains and pharmaceutical supply companies moves Rafarma in a very positive direction and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with such qualified partners that have the confidence in Rafarmato lock in long-term contracts,” Rafarma CEO David Anderson stated in the press release.
“Rafarma’s increase in production and penetration of market share becomes even more assured with the 17 national distributors we have signed to long-term agreements,” he continued. “These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation.”
For more information visit www.rafarma.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
- DoMark International, Inc. (DOMK) Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market
- GNCC Capital, Inc. (GNCP) Nears Completion of the Acquisition of the White Hills Gold Properties
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- International Stem Cell Corp. (ISCO) Initiates IND-Enabling Study in Parkinson's Disease Program
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Announces Engagement of QualityStocks Investor Relations Services
- Rafarma Pharmaceuticals, Inc. (RAFA) Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
- Rainbow Coral Corp. (RBCC) Poised To Gain Share Of $142 Billion Market
- Raptor Resources Holdings Inc. (RRHI) Announces Engagement of QualityStocks Investor Relations Services
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
- The Aristocrat Group Corp. (ASCC) Targets August Sales Debut for RWB Ultra-Premium Gluten-Free Vodka
- The Guitammer Company Inc. (GTMM) Goes Supersonic!
- VentriPoint Diagnostics Ltd. (VPTDF) Announces New Vice-President of Sales and Marketing
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue